Management Ricardo Moro-Vidal, M.D. is the CEO of BioCurex Inc. He is a founder of the company and has been an officer and director since March 2001. Since 1996, Dr. Moro-Vidal has been the President of PBRC, formerly named Curex Technologies Inc., where he developed the RECAF cancer marker concept. From 1980 to 1985, Dr. Moro-Vidal worked in cancer research at the French National Cancer Institute near Paris, France. From late 1985 to 1988, he worked at the University of Alberta, Edmonton on onco-developmental biology. From 1989 to 1996, he was engaged in various entrepreneurial ventures relating to diagnostics and medical instrumentation. Dr. Moro-Vidal received his medical degree from the University of the Republic of Uruguay in 1979. Paul D. Slowey, Ph.D. is the President of BioCurex Inc. Dr. Slowey has been President and CEO of Oasis Diagnostics Corporation since 2007 and Managing Member of Bamburgh Marrsh LLC since 2002. Previously he held various diagnostic positions including; Director of International Sales for OraSure (formerly Epitope), Chief Operating Officer for Saliva Diagnostics, Director of International Sales for Incstar Corp. [now DiaSorin]. He holds a B.S. (Honors) from Sheffield Polytechnic (England), a Ph.D. in Organic Chemistry from the University of Newcastle-Upon-Tyne (England) and Post-Doctoral Fellowships from University of Victoria and Memorial University of Newfoundland (Canada). Denis R. Burger, Ph.D. is BioCurex's Chairman of the Board. Prior to joining the Company, he had been Managing Director of Sovereign Ventures, LLC, a biotech investment and consulting firm. He was Chairman and CEO of AVI BioPharma, Inc., a drug development company using gene targeted therapeutics, from 1997 to 2007 and founding Chairman of Epitope, Inc., a developer of diagnostic products, from 1981 to 1990. He is currently a director of Trinity Biotech PLC, a diagnostic products developer, and Lorus Therapeutics, a cancer therapeutics company. Earlier in his career, he was a Professor of Microbiology and Immunology, an Associate Professor of Surgery and the Director of the Histocompatibility Testing Laboratory at Oregon Health Sciences University. He holds a B.A. degree in Bacteriology and Immunology from the University of California at Berkeley, and an M.S. and Ph.D. in Microbiology and Immunology from the University of Arizona, Tucson. Gladys Chan, C.G.A. Ms. Chan is our CFO. She has been the Controller at BioCurex since July 2005. From September 2004 to June 2005, Ms. Chan served as Senior Accountant at DTI Dental Technologies Inc. From January 2003 to August 2004, Ms. Chan served as Controller of Legal Play Entertainment, Inc., predecessor to Synthenol, Inc. (OTCBB: STHL). Ms. Chan is a designated Certified General Accountant. |